Table 1 Summary of representative studies on the combination of radiotherapy with immunotherapy in main cancer types investigated to date
Cancer type | Patient Characteristics | Number of patients | Status of TMB/MSI/MMR/PD-L1 | Treatment | Outcome | References |
|---|---|---|---|---|---|---|
Melanoma | advanced melanoma | 25 | Not Specified | RT + nivolumab or pembrolizumab | CR&PR&SD&PD in irradiated lesions: 24,12,24,32%;in nonirradiated lesions: 20, 19, 12, 40% | [25] |
metastatic melanoma | 59 | Not Specified | 17:RT + nivolumab or pembrolizumab 42:nivolumab or pembrolizumab | RT + anti-PD-1 therapy vs anti-PD-1 therapy, ORR: 64.7% VS 33.3%; | [26] | |
metastatic melanoma | 101 | Not Specified | 70: concurrent radiotherapy with ipilimumab (Ipi-RT); 31 ipilimumab alone | OS significantly increased (19 vs 10 months). Median PFS marginally increased (5 vs 3 months). CR rate significantly increased (25.7% vs 6.5%), OR rate increaed (37.1% vs 19.4%). | [24] | |
NSCLC | recurrence after at least 1 prior platinum-containing regimen | 1736 (18 studies) | Not Specified | RT + nivolumab, or pembrolizumab, or ipilimumab | Local Control Rate (CR + PR + S): 70.7%; median OS: 12.4 months; PFS: 4.6 months;Distant/Abscopal Response Rate (CR + PR + S):41.3%;Toxicity ≥Grade 3:20.0% | [27] |
Solid tumors | metastatic solid tumor previously treated with standard-of-care therapy | 73 (27 cancer types) | Not Specified | RT + pembrolizumab | overall ORR: 13.2%; Median OS: 9.6 months; Median PFS: 3.1 months; nonirradiated ORR: 26.9% | [34] |